Penn State Startup Working on Novel Approach to Treatment of Complications of Flu and Other Respiratory Illnesses Like COVID-19
“We are treating the inflammatory disease by crippling the cytokine storm.”
Invent Penn State
November 30, 2020
The Opportunity
Highly contagious viruses like Influenza A and B, and SARS-CoV-2, are significant causes of morbidity and mortality. Most treatments for flu and COVID-19 – and the secondary infections that typically lead to hospitalization and can even cause death – focus on the virus. Respana is different. We’re focused on altering the patient’s inflammatory immune response to the virus, not the virus itself.
Management
With a seasoned management team with over 100 years experience in the life sciences, Respana is currently seeking strategic partners to accelerate commercialization.
Read moreOur Technology
Respana’s proprietary therapeutic mAb (RT-002) addresses inflammatory conditions associated with respiratory diseases, including influenza and COVID-19.
Read moreVirtual Pitch
Respana has been selected as a semifinalist for the 2020 North America Advance Biotech Grant program. View our pitch to see how we are pioneering biotherapeutic development to support human health.
View videoAbout Us
Respana Therapeutics, Inc., is an early stage company developing therapeutics that modulate the immune response to lung disease caused by viral infection.
Tim Pelura
President & CEO
Andy Agrawal
Vice President
Michele Washko
COORespana in the News
Catch the latest news and updates from the members of the Respana team.
Mind the Gaps: A Perspective from the World of Academic Spinouts
Mind the Gaps: A Perspective from the World of Academic Spinouts
“Addressing technical gaps, gaps in funding, and gaps in expertise.”
Emerging BioTalk
November 11, 2020
Respana Therapeutics receives support from Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program
“Funding Will Be Used to Advance the Company’s Novel Monoclonal Antibody.”
For Immediate Release
September 1, 2020